Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 26, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	128,005	176,683	103,966	113,582	137,620	396,635
Market Cap Growth	-25.00%	69.94%	-8.47%	-17.47%	-65.30%	-
Enterprise Value	210,665	210,197	44,042	-6,736	-150,494	-63,944
Last Close Price	10650.00	14700.00	8650.00	9450.00	11450.00	33000.00
PE Ratio	40.59	7.92	-	6.47	-	-
Forward PE	-	12.01	12.01	12.01	12.01	-
PS Ratio	8.88	12.33	150.88	701.81	-	-
PB Ratio	0.26	0.35	0.20	0.21	0.32	0.69
P/TBV Ratio	0.35	0.48	0.26	0.28	0.32	0.69
EV/Sales Ratio	14.62	14.67	63.92	-	-	-
Debt / Equity Ratio	0.25	0.28	0.17	0.21	0.01	0.01
Debt / EBITDA Ratio	-	-	-	9.11	-	-
Net Debt / Equity Ratio	-0.02	-0.06	-0.26	-0.34	-0.69	-0.78
Net Debt / EBITDA Ratio	0.15	0.66	2.89	-14.65	2.52	27.01
Net Debt / FCF Ratio	0.10	0.32	1.95	1.71	2.92	27.54
Asset Turnover	0.02	0.02	0.00	0	-	-
Inventory Turnover	0.94	1.18	0.89	0.01	-	-
Quick Ratio	0.92	1.05	1.53	2.24	7.26	32.70
Current Ratio	1.17	1.27	1.72	2.31	7.46	32.74
Return on Equity (ROE)	-1.07%	0.81%	-10.38%	-0.59%	-42.08%	-2.07%
Return on Assets (ROA)	-6.58%	-5.71%	-5.35%	0.10%	-13.89%	-3.01%
Return on Capital Employed (ROCE)	-13.30%	-11.50%	-11.00%	0.20%	-26.80%	-3.10%
Earnings Yield	12.31%	12.62%	-31.66%	15.47%	-153.65%	-1.86%
FCF Yield	-58.75%	-52.57%	-65.49%	-95.65%	-74.36%	-4.13%
Buyback Yield / Dilution	0.20%	-0.44%	0.22%	-	-16.46%	-20.98%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.